FDA warned Thriftmaster Texas over unapproved CBD drugs and CBD-added foods, citing disease and COVID-19 claims and an unsafe food additive.
What happened
In November 2022, FDA reviewed the company’s websites and social media accounts. FDA found orders for CBD products with claims that they may treat or prevent diseases including COVID-19 and Alzheimer’s, and found CBD added to dried mango, dried pineapple, and gummies. FDA also said the two CBD inhalers are especially concerning because oral inhalation may harm airways.
What FDA found
The CBD products are unapproved new drugs because the company sells them with claims to treat or prevent disease and FDA has not approved them.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The CBD products are misbranded because their labeling does not give adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)The dried mango, dried pineapple, and gummies are adulterated foods because they contain CBD, which is an unsafe food additive.
FD&C Act section 402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)Putting these CBD-added foods into interstate commerce is a prohibited act.
FD&C Act section 301(ll), 21 U.S.C. 331(ll)Website and social media claims that the CBD products may treat COVID-19, Alzheimer’s, and other conditions show the products are intended for drug use.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)CBD is not generally recognized as safe for conventional food, and no food additive rule authorizes its use.
FD&C Act sections 201(s) and 409(a), 21 U.S.C. 321(s) and 348(a)
What FDA wants
FDA asks the company to take immediate action to stop selling unapproved products claimed to treat COVID-19 and to notify FDA in writing within 15 working days of steps taken to correct the violations, including how it will prevent recurrence.
Who should pay attention
- companies selling CBD or hemp-derived products as drugs or foods
- brands and retailers that buy or resell CBD edibles and inhalers
- firms making disease or COVID-19 claims for unapproved products
This is a summary. Read the original letter on fda.gov.